title: One size does not fit all: can we choose the best sequence of treatment in asymptomatic castration-resistant prostate cancer patients?
authors.affiliation: Department of Cancer Medicine, Institut Gustave Roussy and University of Paris Sud, Villejuif, France.
authors.forename: Yohann
authors.initials: Y
authors.lastname: Loriot
authors.affiliation: Department of Cancer Medicine, Institut Gustave Roussy and University of Paris Sud, Villejuif, France; Drug Development Department, SITEP, Institut Gustave Roussy, Villejuif, France. Electronic address: christophe.massard@gmail.com.
authors.forename: Christophe
authors.initials: C
authors.lastname: Massard
authors.affiliation: Department of Cancer Medicine, Institut Gustave Roussy and University of Paris Sud, Villejuif, France.
authors.forename: Karim
authors.initials: K
authors.lastname: Fizazi
mesh_terms: D000736:Androstenes / Q000008:administration & dosage*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D001859:Bone Neoplasms / Q000556:secondary*; D000077143:Docetaxel; D006801:Humans; D008175:Lung Neoplasms / Q000556:secondary*; D008297:Male; D064129:Prostatic Neoplasms, Castration-Resistant / Q000188:drug therapy* / Q000473:pathology*; D043823:Taxoids / Q000008:administration & dosage*
chemical_list: D000736:Androstenes; D043823:Taxoids; D000077143:Docetaxel; C089740:abiraterone